Anhua Biomedicine

Guangzhou Anhua Biomedicine is a clinical-stage biotechnology company headquartered in China, specializing in the discovery and development of innovative small molecule drugs for chronic metabolic diseases. The company's research efforts are primarily focused on addressing unmet medical needs in hyperuricemia and gout, as well as related complications such as chronic kidney disease. Its lead candidate, ANP-090, is a highly potent and selective URAT1 inhibitor that has demonstrated a promising safety and efficacy profile in clinical trials. By leveraging its internal R&D platform, Anhua Biomedicine aims to provide optimized therapeutic options for patients suffering from metabolic disorders globally.